The goal of Michigan Prostate SPORE Biospecimen/Pathology Core is to collect biological materials with associated clinical information to facilitate translational prostate cancer research. The Core places patient confidentiality and clinical care as a top priority. As a coordinated effort between pathology, urology, medical oncology, radiation oncology, and Michigan Prostate SPORE researchers, the Core has developed a unified informatics infrastructure that provides researchers a wide range of annotated samples. The specific goals of the Core include: (1) Protection of patient welfare. The highest priority is given to assure that no research protocol compromises pathology diagnosis or tumor staging. (2) Acquisition and processing of prostate tissues for research. The Core assures that the widest range of prostate tissues and derived biomolecules are available from various sources, including benign prostate tissue from patients without any known prostatic disease, clinically localized prostate cancer, and metastatic hormone refractory prostate cancer (Michigan Legacy Tissue Program). (3) High quality pathologic review of prostate tissues. Expert GU pathologists assure uniform review of prostate tissue samples. (4) Pathology consultation for the purpose of designing translational research projects. This service focuses on determining the types of tissues and amount required for the successful completion of the research projects. (5) Quality assessment of prostate tissues and clinical data. The Biospecimen/Pathology Core staff regularly evaluates frozen and formalin fixed tissues for adequacy. (6) Development of technology appropriate for pathology-based translational research. New technologies such as integrative high-throughput sequencing, RNA in situ hybridization, and single-cell analysis have been introduced. (7) Provide support to ongoing clinical studies. The Core will continue to provide tissue procurement services and/or high-quality pathology reviews of specimens from patients enrolled in various clinical trials and studies. (8) Maintenance of clinical and pathology data with links to molecular studies. The Core will continue to expand the detailed clinical and pathology database conforming to the NCI's Common Data Elements (CDE) guidelines, permitting queries between molecular findings and clinically relevant outcomes. In summary, the Core will provide SPORE investigators with a wealth of carefully annotated samples for translational research, while maintaining the highest level of clinical care and patient confidentiality.

Public Health Relevance

The Michigan Prostate SPORE Biospecmen / Pathology Core collects, annotates, and stores critical prostate cancer related biospecimens required for patient-oriented research. It also has the capabilities for the morphological analysis of tissues and molecular analysis of tissues and biofluids. Our continued goal is to decrease the morbidity and mortality of prostate cancer through innovative research that is supported by biospecimen resources, database and informatics support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA186786-06
Application #
9791698
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Zhang, Yajia; Pitchiaya, Sethuramasundaram; Cie?lik, Marcin et al. (2018) Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet 50:814-824
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Niknafs, Yashar S; Pandian, Balaji; Gajjar, Tilak et al. (2018) MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. Neoplasia 20:1144-1149
Xiao, Lanbo; Tien, Jean C; Vo, Josh et al. (2018) Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer Res 78:5731-5740
Piert, Morand; Shankar, Prasad R; Montgomery, Jeffrey et al. (2018) Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Res 8:23
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Rice, John D; Tsodikov, Alex (2017) Semiparametric profile likelihood estimation for continuous outcomes with excess zeros in a random-threshold damage-resistance model. Stat Med 36:1924-1935
Shen, Rex; Luo, Lan; Jiang, Hui (2017) Identification of gene pairs through penalized regression subject to constraints. BMC Bioinformatics 18:466

Showing the most recent 10 out of 65 publications